Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proton Rahman

Showing results (161-170 of 260) with videos related to

Pageof 26
Sort By:
BMJ Open|November 21, 2014
Classification of osteoarthritis phenotypes by metabolomics analysisWeidong Zhang, Sergei Likhodii, Yuhua Zhang, et al.
Annals of the Rheumatic Diseases|September 13, 2022
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal studyRobert B M Landewé, Denis Poddubnyy, Proton Rahman, et al.
BMC Rheumatology|September 24, 2020
Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registryProton Rahman, Philip Baer, Ed Keystone, et al.
The Journal of Rheumatology|May 1, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
The Journal of Rheumatology|February 15, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Rheumatology and Therapy|June 14, 2024
Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Pageof 26

Showing results (161-170 of 260) with videos related to

Sort By:
Pageof 26
BMJ Open|November 21, 2014
Classification of osteoarthritis phenotypes by metabolomics analysisWeidong Zhang, Sergei Likhodii, Yuhua Zhang, et al.
Annals of the Rheumatic Diseases|September 13, 2022
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal studyRobert B M Landewé, Denis Poddubnyy, Proton Rahman, et al.
BMC Rheumatology|September 24, 2020
Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registryProton Rahman, Philip Baer, Ed Keystone, et al.
The Journal of Rheumatology|May 1, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
The Journal of Rheumatology|February 15, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Rheumatology and Therapy|June 14, 2024
Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Pageof 26